Skip Nav

Contact Us

Chondrosarcoma CS Foundation, Inc.

Thank you for your interest in our company. Complete the form below to send us an email, or simply give us a call. We're looking forward to working with you.

  • 301-352-3042

Thank You!

Your message has been sent.

Oops, message not sent.

Please make sure fields are complete.


Empowering Patients to Speak Up for Your Health

Check out the video hosted by Memorial Sloan Kettering entitled: Empowering Patients: Speak Up for Your Health. The link is listed below as well as the transcript. The Empowered Patient: Speak Up for Your Health | Memorial Sloan Kettering Cancer…

Read Article

Inhibrx Announces Positive Interim Results from the Phase 1 Trial of INBRX-109 in Chondrosarcoma Patients

SAN DIEGO, Nov. 11, 2020 /PRNewswire/ –InhibRx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development, announced updated interim results today from a Phase 1 clinical trial evaluating the efficacy and safety of…

Read Article

Chondrosarcoma (CS) Foundation Celebrates It First Anniversary

This coming Friday will be the Chondrosarcoma Foundation’s first anniversary. Last year, on May 14, 2020 during the beginning of the pandemic, we launched the Chondrosarcoma Foundation by bringing CS Foundation web site on-line. My…

Read Article

Inbrx-109 Phase 1 Trial Shows Positive Interim Results in Patients with Chondrosarcoma

November 13, 2020 Dylann Cohn-Emery Treatment with the investigation agent INBRX-109 induced responses and decreased the tumor burden in a cohort of patients with chondrosarcoma, according to interim efficacy and safety findings a phase 1 trial in…

Read Article

INBRX-!09 on the Fast Track for Metastatic Conventional Chondrosarcoma Patients

Inhibrx Granted Fast Track Designation for INBRX-109 for the Treatment of Unresectable or Metastatic Conventional Chondrosarcoma Patients Registration-enabling study expected to begin dosing in the second or third quarter of this year

Read Article

Is the IDH Mutation a Good Target for Chondrosarcoma Treatment?

Elena Cojocaru, Christopher Wilding, Bodil Engelman, Paul Huang & Robin L. Jones Current Molecular Biology Reports volume 6, pages1–9(2020)Cite this article Is the IDH Mutation a Good Target for Chondrosarcoma Treatment? |…

Read Article

Multigenerational and Transgenerational Effects of Dioxins As the Cause of Cancer

Abstract Dioxins are ubiquitous and persistent environmental contaminants whose background levels are still reason for concern. There is mounting evidence from both epidemiological and experimental studies that paternal exposure to the most potent…

Read Article

In Memory of Sebastian

Sebastien passed away July 14, 2020 from dedifferentiated chondrosarcoma. This narrative was written and submitted by his sister Stephanie Desjardins. In April 2019, my brother was diagnosed with a chondrosarcoma of chest wall on the right side…

Read Article

Contact Information

If you would like to learn more about CS Foundation or if you would like to learn more about the resources we provide to patients, families, caregivers, and physicians, please contact us by phone or send us a message.

**A Registered 501c3 Non-Profit Charity Organization. All donations are tax-deductible.**

Send a Message